Pharmaceutical industry

Success Story: Infiniti Research helps a Pharmaceutical Blister Packaging Manufacturer Drive Sales and Increase Profits Using Industry-Specific Market Research

Tuesday, July 7, 2020 - 2:33pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200707005087/en/
    Industry-Specific Market Research for a Pharmaceutical Blister Packaging Manufacturer (Graphic: Business Wire)
    The client is a manufacturer in the pharmaceutical blister packaging market , based out of Luxembourg.
  • For the pharmaceutical blister packaging market, in-depth access to extensive and comprehensive industry specific market research is highly crucial.
  • This provided the pharmaceutical blister packaging market client with access to insights into more than a 1000 high-growth, niche markets.
  • Business impact of the industry-specific market research for the pharmaceutical blister packaging market client:
    By subscribing to Infinitis knowledge store, the client was able to gain access to industry-specific market research, get ahead in the competitive pharmaceutical blister packaging market, and stay updated on the ever-changing technology landscape.

Alliance for Regenerative Medicine Responds to EU Pharmaceutical Roadmap

Tuesday, July 7, 2020 - 7:00am

Leading international advocacy group calls for effective regulation, clinical trial support, and value-based reimbursement that benefits patient access to ATMPs

Key Points: 
  • Leading international advocacy group calls for effective regulation, clinical trial support, and value-based reimbursement that benefits patient access to ATMPs
    The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry.
  • It is critical that the EU Pharmaceutical Strategy furthers the ability of patients to benefit from these transformative therapies and supports vigorous growth in the ATMP sector to drive further advances.
  • ARM looks forward to further consultation on the EU Pharmaceutical Strategy.
  • For more information or for media requests, please contact Kaitlyn (Donaldson) Dupont from the Alliance for Regenerative Medicine at kdonaldson@alliancerm.org or Consilium Strategic Communications at ARM@consilium-comms.com .

Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review

Tuesday, July 7, 2020 - 12:40am

OSAKA, Japan, July 6, 2020 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that the United States Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for DE-128 (MicroShunt) for review.

Key Points: 
  • OSAKA, Japan, July 6, 2020 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that the United States Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for DE-128 (MicroShunt) for review.
  • The substantive review, which traditionally spans 180 days from the FDA's receipt of the PMA final module, is an in-depth review following which the FDA will make a decision as to whether the PMA is approved.
  • As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices.
  • Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries.

Publication of transparency notifications

Monday, July 6, 2020 - 5:30pm

Based in Lige, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals.

Key Points: 
  • Based in Lige, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals.
  • Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system.
  • Hyloris portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics).
  • Additionally, Hyloris has 12 product candidates in various stages of development across the Companys wider portfolio.

Aesthetics Biomedical® Names World Renowned Experts to Prestigious Clinical Advisory Board

Monday, July 6, 2020 - 4:00pm

Grant Stevens, Steven Dayan, Michael DeWolfe, and Stephen Ronan have been appointed to the company's Clinical Advisory Board (CAB).

Key Points: 
  • Grant Stevens, Steven Dayan, Michael DeWolfe, and Stephen Ronan have been appointed to the company's Clinical Advisory Board (CAB).
  • With this group of renowned physicians serving as our Clinical Advisory Board, they will help us achieve our goals and maintain the highest company standards while forging new paths and standards within the industry.
  • We have meticulously selected this impressive team to continue to establish ABM's leadership within the field of aesthetics" says MaryAnn Guerra, CEO of Aesthetics Biomedical.
  • CAB members will also represent Aesthetics Biomedical at industry events, conferences, drafting of scientific papers and participate in clinical trials.

Recce Pharmaceuticals Announces Resignation of Director & Chief Research Officer Dr. Graham Melrose

Monday, July 6, 2020 - 2:03pm

SYDNEY, Australia, July 06, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melroses executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board.

Key Points: 
  • SYDNEY, Australia, July 06, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melroses executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board.
  • The Company is now well setup to pursue its objectives, with expanding indications across a range of significant and unmet infectious diseases.
  • A pioneer in synthetic antibiotic development, Dr. Melrose founded Recce Pharmaceuticals Ltd in 2008, later co-inventing RECCE antibiotics with Executive Director Michele Dilizia.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Anixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19 Compounds

Monday, July 6, 2020 - 2:00pm

As previously announced, Anixa and OntoChem have identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).

Key Points: 
  • As previously announced, Anixa and OntoChem have identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).
  • Based on initial identification of the Mpro scaffold compound, Anixa and OntoChem have created a new in silico library of analog compounds that will be evaluated through additional in silico screening to choose which additional compounds may be synthesized and evaluated in biological assays.
  • We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.
  • You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

A Top Five Global Life Sciences Giant Goes Live with ValGenesis VLMS Across Its Global Sites

Monday, July 6, 2020 - 1:37pm

For over a century, this iconic global company has been developing differentiated medicines for several devastating diseases that are plaguing the world.

Key Points: 
  • For over a century, this iconic global company has been developing differentiated medicines for several devastating diseases that are plaguing the world.
  • It is recognized as the group leader in sustainability within the pharmaceutical, biotechnology, and life science industries for many years.
  • The ValGenesis VLMS has enabled a single source of truth and standardized validation processes across this company's multiple global sites, resulting in huge process and operational efficiencies.
  • Enabled to achieve complete digital transformation of the validation process through the ValGenesis VLMS, the company and ValGenesis are partnering to develop an innovative solution for unique validation activities in the life sciences business process.

Cell Expansion Market Worth $30.1 billion by 2025 - Exclusive Report by MarketsandMarkets™

Monday, July 6, 2020 - 1:30pm

CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.

Key Points: 
  • CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.
  • The media segment accounted for the largest share of the consumables segment in the market.
  • Based on end-users, the market has been segmented into research institutes, biotechnology & biopharmaceutical companies, cell banks, and other end users (includes hospitals, diagnostic centers, and laboratories).
  • In 2019, biotechnology & biopharmaceutical companies were the largest end-users in the Cell Expansion Market, and the trend is the same throughout the forecast period.

Cell Expansion Market Worth $30.1 billion by 2025 - Exclusive Report by MarketsandMarkets™

Monday, July 6, 2020 - 1:30pm

CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.

Key Points: 
  • CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.
  • The media segment accounted for the largest share of the consumables segment in the market.
  • Based on end-users, the market has been segmented into research institutes, biotechnology & biopharmaceutical companies, cell banks, and other end users (includes hospitals, diagnostic centers, and laboratories).
  • In 2019, biotechnology & biopharmaceutical companies were the largest end-users in the Cell Expansion Market, and the trend is the same throughout the forecast period.